News

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...
Meds taken by millions of Americans at night linked to disability
Researchers from Penn State University and Taipei Medical University analyzed five years worth of data around insomnia and ...